Constipation is common in cancer, from pain medicines, some chemotherapy, and eating, drinking and moving less. Anyone starting a strong opioid should be prescribed a regular laxative too. Tell your team if you are constipated. Tell them straight away about severe tummy pain, vomiting, or sudden diarrhoea or leaking stool after constipation, or new leg weakness or numbness.
Constipation in cancer has many possible causes: opioids, anticholinergics (including antidepressants and antihistamines), antacids, diuretics, neurotoxic chemotherapy (the NCI names vinca alkaloids, oxaliplatin, taxanes and thalidomide), low intake of fluid and fibre, immobility, hypercalcaemia and other metabolic disorders, a growing tumour, and spinal cord injury or compression. The NCI's assessment is a history of the bowel pattern, diet and medicines with a physical examination; a digital rectal examination may be part of it, to rule out impaction in the rectum, and MASCC says the examination should ideally include one. In immunocompromised patients the NCI says manipulation of the rectum and anus should be avoided: no rectal examinations, suppositories or enemas. If constipation persists despite preventive laxatives, obstruction and impaction are ruled out and other causes such as hypercalcaemia treated. Diarrhoea or leakage of stool in a constipated patient suggests impaction: the NCI calls leakage with nausea, vomiting, abdominal pain and dehydration virtually diagnostic.
Prevention with opioids is the best supported step: NICE CG140 says to prescribe a regular laxative for all patients starting a strong opioid, MASCC suggests routine co-prescription of a laxative or an opioid antagonist (level IV), and the NCI says a bowel regimen continues for as long as the opioid does, titrated to one unforced bowel movement every 1 to 2 days. On which laxative, the sources differ. The NCI starts a scheduled stimulant such as senna, says adding a stool softener offers no further benefit, and finds no evidence to prefer one class when constipation persists; MASCC recommends polyethylene glycol first; the Cochrane review (2015) found laxatives of similar effectiveness on limited evidence. The NCI does not advise bulk-forming agents for opioid-induced constipation. The vincristine label recommends a routine prophylactic regimen for all patients and warns that impaction can be in the upper colon with an empty rectum.
For opioid-induced constipation, a peripherally acting mu-opioid receptor antagonist is an option: NICE recommends naloxegol as an option when constipation has not adequately responded to laxatives and naldemedine as an option after laxative treatment; methylnaltrexone is given by subcutaneous injection. MASCC says these medicines should always be considered in opioid-induced constipation (level I). The NCI says they are not used if postoperative ileus or mechanical bowel obstruction is suspected. Sources differ on whether laxatives stop when one is started.
The ESMO guideline (2018) could not be read, so its graded recommendations are not reported here. The reader's own team's protocol comes first.
Why: The history, with an examination, is how the possible causes are found. The NCI asks what is normal for the patient and whether the symptom is a recent change.
“A thorough history of the patient’s bowel pattern, dietary changes, and medications, along with a physical examination, can identify possible causes of constipation.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI lists medicines among the causes, and removing a cause where that is possible is part of managing constipation. Its pain summary adds that 5-HT3 antiemetics such as ondansetron could worsen constipation in people taking opioids.
“Constipation is frequently the result of autonomic neuropathy caused by vinca alkaloids, oxaliplatin, taxanes, and thalidomide.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI lists spinal cord compression among the causes of constipation, and NICE treats its signs in a person with cancer as an oncological emergency.
“Immediately contact the MSCC coordinator if a person with a past or current diagnosis of cancer presents with the symptoms or signs of cord compression listed in box 1. Treat this as an oncological emergency.”
NICE 2023 · NICE recommendation 1.3.2 (not graded)
Why: A rectal examination shows whether stool is impacted in the rectum. The NCI lists it among tests that may be part of the evaluation, and MASCC says the examination should ideally include one.
“Digital rectal exam: Done to rule out fecal impaction at the level of the rectum.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI says these can lead to anal fissures or abscesses, which let infection in.
“In immunocompromised patients, manipulation of the rectum and anus should be avoided (i.e., no rectal examinations, no suppositories, and no enemas).”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI's table marks several laxatives as contraindicated or to be avoided in bowel obstruction, and it lists hypercalcaemia among the metabolic causes.
“After obstruction and impaction are ruled out, other causes of constipation (such as hypercalcemia) are treated.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: Liquid stool passing around a hard mass looks like diarrhoea but is a sign of impaction.
“Movement of stool around the impaction may result in diarrhea, which can be explosive.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI says constipation is made worse by dehydration and inactivity, and lists lack of privacy among its causes. MASCC adds that changes to diet and exercise have a limited role in advanced cancer.
“Provide a toilet or bedside commode and appropriate assistive devices; avoid bedpan use whenever possible.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: NICE says constipation affects nearly all patients on strong opioids. The NCI gives 40% to 95% and says patients generally do not develop tolerance to it.
“Prescribe laxative treatment (to be taken regularly at an effective dose) for all patients starting strong opioids.”
NICE 2012 · NICE recommendation 1.1.18 (not graded)
Why: Opioids reduce peristalsis and a stimulant increases the bowel's motor activity; the NCI says adding a stool softener offers no further benefit. MASCC instead recommends polyethylene glycol first, so local protocols differ.
“A scheduled stimulant laxative, such as senna, is started with opioid initiation. The addition of a stool softener offers no further benefit.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI cites one study suggesting the laxative should be titrated to bowel function and not set by the opioid dose.
“Laxatives are titrated to a goal of one unforced bowel movement every 1 to 2 days.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI's table says bulk producers must be taken with plenty of water to reduce the risk of bowel obstruction.
“Not advised for opioid-induced constipation.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The label says vincristine constipation can be an impaction in the upper colon, or a paralytic ileus, with an empty rectum that may mislead the examiner, and that a flat film of the abdomen is useful in showing it.
“A routine prophylactic regimen against constipation is recommended for all patients receiving Vincristine Sulfate Injection.”
Why: The NCI says these block opioid receptors in the gut and have a restricted ability to cross into the brain; in the study it cites pain scores were unchanged. NICE recommends naloxegol and naldemedine as options, not as a requirement.
“Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives.”
NICE 2015 · NICE technology appraisal recommendation 1.1 (not graded)
Why: The NCI says these medicines are not used in that setting, and its table lists them as contraindicated in bowel obstruction.
“These agents are not used if postoperative ileus or mechanical bowel obstruction is suspected.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: The NCI says enemas lubricate the bowel and soften the stool, and warns that too many can perforate it. Its patient page says suppositories and enemas may lead to bleeding or infection in some people with cancer.
“The patient may need to be digitally disimpacted if the stool is within reach.”
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025
Why: NICE asks for laxatives to be optimised first. MASCC notes that lowering the opioid dose does not improve the constipation, though switching opioid sometimes does.
“Optimise laxative treatment for managing constipation before considering switching strong opioids.”
NICE 2012 · NICE recommendation 1.1.20 (not graded)
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The body whose remit this is, MASCC (2020), makes 15 recommendations, most of them suggestions on level IV or V evidence. Its level I recommendations are that conventional laxatives should be considered first-line in functional constipation (data mainly from the general population; the group recommends polyethylene glycol first) and that peripherally acting mu-opioid receptor antagonists should always be considered in opioid-induced constipation. The other well supported steps are: a regular laxative for all patients starting a strong opioid (NICE CG140 1.1.18; NCI PDQ; MASCC, level IV, a laxative or an antagonist), continued while the opioid continues and titrated to one unforced bowel movement every 1 to 2 days (NCI); ruling out obstruction and impaction, and treating causes such as hypercalcaemia, when constipation persists (NCI); no rectal examination, suppositories or enemas in immunocompromised patients (NCI); and an opioid antagonist as an option when laxatives have not worked (NICE TA345 and TA651; Cochrane 2022, moderate-certainty evidence that naldemedine and methylnaltrexone may improve bowel function over two weeks). The sources differ on three points and all are shown. On laxative choice, the NCI starts a stimulant and says a softener adds nothing, MASCC recommends polyethylene glycol, NICE names no class and Cochrane found laxatives similar on limited evidence. On combining treatments, the NCI pain summary stops laxatives before an opioid antagonist is started, while NICE TA651 says an antagonist and a conventional laxative are commonly used together and MASCC suggests adding or switching to a laxative if the antagonist does not work. On fluids, fibre and exercise, the NCI encourages them and MASCC says they have a limited role in advanced cancer. The ESMO guideline (2018) could not be read and is not represented.
Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 · NICE 2012 · US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · NICE 2015 · NICE 2020 · Cochrane Database of Systematic Reviews (Candy et al.) 2022 · Cochrane Database of Systematic Reviews (Candy et al.) 2015
Where it differs: For preventing opioid constipation the NCI pain summary starts a scheduled stimulant such as senna and adds that a stool softener gives no further benefit. When constipation persists it lists bisacodyl, polyethylene glycol, magnesium hydroxide, lactulose, sorbitol and magnesium citrate as appropriate and says no class can be recommended over another. MASCC recommends polyethylene glycol as the first-line treatment for constipation in advanced cancer, individualised because the volume, taste and side effects can limit its use. NICE CG140 asks for a laxative taken regularly at an effective dose and names no class.
Evidence: The Cochrane review of laxatives in palliative care (2015) found laxatives of similar effectiveness from a few small trials, none of which tested polyethylene glycol or any rectal treatment. MASCC grades conventional laxatives first-line as level I for functional constipation, on data mainly from the general population, and level V for secondary constipation; its preference for polyethylene glycol rests on general-population data, expert opinion and clinical experience. Three of its authors declared personal fees from Kyowa Kirin. Whether ESMO prefers an osmotic or a stimulant laxative could not be checked.
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 · NICE 2012 · Cochrane Database of Systematic Reviews (Candy et al.) 2015
Where it differs: NICE recommends naloxegol as an option when constipation has not adequately responded to laxatives, and naldemedine as an option for adults who have had laxative treatment. The NCI's table of agents says to give opioid antagonists only if other drugs have failed, and its pain summary says laxatives are discontinued before one is started. MASCC says the antagonists should always be considered in opioid-induced constipation and accepts one in place of a laxative for prevention, while noting there are no data to support co-prescribing one for prevention. NICE TA651 says treatment may be an antagonist alone but that commonly an antagonist and a conventional laxative are used together; MASCC suggests adding or switching to a conventional laxative when an antagonist has not worked.
Evidence: Cochrane 2022: moderate-certainty evidence that oral naldemedine in people with cancer, and subcutaneous methylnaltrexone in people receiving palliative care, may improve bowel function over two weeks; the evidence on serious adverse events is low certainty. MASCC grades its recommendation level I and the add-or-switch advice level V. No trial read compares an antagonist with and without a continued laxative.
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · NICE 2015 · NICE 2020 · Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 · Cochrane Database of Systematic Reviews (Candy et al.) 2022
Where it differs: The NCI lists a digital rectal examination among the tests that may be part of the evaluation, and in the same summary says that in immunocompromised patients there should be no rectal examinations, suppositories or enemas. Separately it says rectal agents should be avoided in patients at risk of low platelets, low white cells or mucositis, and its pain summary says suppositories and enemas are generally avoided in neutropenia or thrombocytopenia. MASCC says the examination should ideally include a digital rectal examination, and suggests suppositories and enemas only where there is stool in the rectum or descending colon and other measures have not worked.
Evidence: The NCI gives the reasoning that anal fissures and abscesses are portals of entry for infection and cites no trial. MASCC grades its suggestion on suppositories and enemas level V and says there are no randomised trials of rectal measures in advanced cancer.
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020
Where it differs: The NCI encourages fluids, fibre and regular exercise before or alongside laxatives. MASCC says such lifestyle changes have a limited role in patients with advanced cancer, are generally unsuitable for them, and improve functional but not opioid-induced constipation in other groups. The NCI's patient page adds that high-fibre foods and fibre supplements can make constipation worse for some people.
Evidence: MASCC: level V, suggestion; it says there is no evidence that these strategies work in advanced cancer. The NCI summaries are not graded.
US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 · Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 · US National Cancer Institute 2025
Where it differs: A European expert panel proposes early recognition, fluids, exercise and standard laxatives first, the Bowel Function Index to measure severity and response, and gut-restricted or peripherally acting opioid antagonists second line, adding that a combination of interventions may be needed.
Evidence: Expert opinion, read as an abstract only. The record lists the drug company Kyowa Hakko Kirin as funder.
United European Gastroenterology Journal (Farmer et al.; funder listed as Kyowa Hakko Kirin) 2019
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Regular laxative for all patients starting strong opioids | NICE recommendation 1.1.18 (not graded) | NICE 2012 |
| Tell patients constipation affects nearly all patients on strong opioids “Inform patients that constipation affects nearly all patients receiving strong opioid treatment.” | NICE recommendation 1.1.17 (not graded) | NICE 2012 |
| A bowel regimen starts with the opioid and continues with it “a bowel regimen should be initiated when opioids are prescribed and continued for as long as the patient takes them.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Patients prescribed opioid analgesics should be routinely co-prescribed laxatives (or a peripherally acting opioid antagonist) | Level of evidence IV; category of guideline: suggestion | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| No laxative class can be recommended over another when opioid constipation persists despite prevention “There is no evidence to recommend one laxative class over another in this setting.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Laxatives are of similar effectiveness in palliative care, on limited evidence “This second update found that laxatives were of similar effectiveness but the evidence remains limited due to insufficient data from a few small RCTs.” | Cochrane review; certainty not stated in the abstract | Cochrane Database of Systematic Reviews (Candy et al.) 2015 |
| Conventional laxatives should be considered first-line in functional constipation (the group recommends polyethylene glycol first) | Level of evidence I; category of guideline: recommendation; data primarily from the general population | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| Conventional laxatives should be considered first-line in secondary constipation | Level of evidence V; category of guideline: suggestion | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| Peripherally acting mu-opioid receptor antagonists should always be considered in opioid-induced constipation | Level of evidence I; category of guideline: recommendation | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| If an opioid antagonist does not work, reassess and consider adding or switching to a conventional laxative or specialist medication | Level of evidence V; category of guideline: suggestion | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| Naldemedine after laxative treatment “Naldemedine is recommended, within its marketing authorisation, as an option for treating opioid-induced constipation in adults who have had laxative treatment.” | NICE technology appraisal recommendation 1.1 (not graded) | NICE 2020 |
| An opioid antagonist and a conventional laxative are commonly used together “But, commonly a PAMORA and a conventional laxative are used together.” | NICE committee statement (not graded) | NICE 2020 |
| Laxatives are stopped before an opioid antagonist is started “Laxatives are discontinued before peripherally acting opioid antagonists are initiated.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Methylnaltrexone may improve bowel function over two weeks in people receiving palliative care “Moderate-certainty evidence for methylnaltrexone on spontaneous laxations over two weeks suggests subcutaneous methylnaltrexone may improve bowel function in people receiving palliative care, but certainty of evidence for AEs was low.” | Moderate-certainty evidence (GRADE) | Cochrane Database of Systematic Reviews (Candy et al.) 2022 |
| Rectal agents avoided in patients at risk of low platelets, low white cells or mucositis “Rectal agents should be avoided in patients with cancer at risk of thrombocytopenia, leukopenia, and/or mucositis from cancer and its treatment.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Suppositories and enemas generally avoided in neutropenia or thrombocytopenia “Suppositories and enemas are generally avoided in the setting of neutropenia or thrombocytopenia.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Suppositories and enemas only where there is stool in the rectum or descending colon and other measures have not worked | Level of evidence V; category of guideline: suggestion | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| Impaction is treated by hydrating and softening the stool so it can be passed or removed “The primary treatment of impaction is to hydrate and soften the stool so that it can be removed or passed.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| Lifestyle changes such as dietary fibre and exercise have a limited role in advanced cancer | Level of evidence V; category of guideline: suggestion | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
| Vincristine: impaction may be in the upper colon with an empty rectum “Constipation may take the form of upper–colon impaction, and, on physical examination, the rectum may be empty.” | Regulatory label; not graded | Hospira (DailyMed, US National Library of Medicine) 2026 |
| 5-HT3 antiemetics could worsen constipation in people taking opioids “However, they could worsen constipation among patients already taking opioids.” | PDQ summary; not graded | US National Cancer Institute, PDQ Supportive and Palliative Care Editorial Board 2025 |
| A carer should tell the team about fewer than three bowel movements in a week, severe abdominal pain, vomiting or other signs of impaction “Notify the care team if the person has had fewer than three bowel movements in one week or is experiencing severe abdominal pain, vomiting, and other signs of fecal impaction.” | NCI patient information; not graded | US National Cancer Institute 2025 |
| MASCC produced 15 recommendations on assessment, treatment and re-assessment “The group produced 15 recommendations, with varying levels of evidence and so varying categories of guideline.” | Level of evidence I to V with a category of guideline: recommendation, suggestion, or no guideline possible | Supportive Care in Cancer (Davies et al., MASCC Palliative Care Study Group) 2020 |
Shares Oxycodone, Morphine, Strong opioids for cancer pain: starting, titrating, rescue doses and preventing constipation.
Shares Opioid switching and dose conversion in adults with cancer pain, Methylnaltrexone, Morphine, Strong opioids for cancer pain: starting, titrating, rescue doses and preventing constipation.
Shares Opioid switching and dose conversion in adults with cancer pain, Strong opioids for cancer pain: starting, titrating, rescue doses and preventing constipation.
Shares Oxycodone, Opioid switching and dose conversion in adults with cancer pain, Methylnaltrexone, Morphine.
Shares Metastatic spinal cord compression: recognition, MSCC coordinator, MRI, dexamethasone, radiotherapy and surgery, Ondansetron.
Shares Morphine, Strong opioids for cancer pain: starting, titrating, rescue doses and preventing constipation.
Shares Hypercalcaemia of malignancy: assessment, intravenous fluids, bisphosphonate or denosumab, Metastatic spinal cord compression: recognition, MSCC coordinator, MRI, dexamethasone, radiotherapy and surgery.